Advertisement

Exenatide extended-release pre-filled pen (Bydureon® BCise®): a profile of its use

  • Emma D. DeeksEmail author
Adis Drug Q&A
  • 20 Downloads

Abstract

The Bydureon® BCise® pre-filled pen was developed largely to simplify self-administration of exenatide extended-release for patients with type 2 diabetes, being comfortable and intuitive to use, with easy-to-mix medication, sterile and safe needle containment, reliable/accurate dose delivery, and indicators of complete dose delivery and device use. Subcutaneous self-injection with Bydureon BCise involves three simple key steps (mixing, unlocking and pressing against the skin to inject) and has a needle that remains hidden, ensuring sterility and reducing the likelihood of accidental injury. In a single-injection study, the Bydureon BCise pre-filled pen was largely considered ‘easy’/‘very easy’ to use, and had a high rate of successful injection completion, including among lay users with dexterity or visual impairment. As an add-on to diet and exercise or oral glucose-lowering therapy, Bydureon BCise once weekly improved glycaemic control and provided glycaemic benefits over subcutaneous twice-daily exenatide and oral once-daily sitagliptin. Bydureon BCise was also generally well tolerated and appeared to have a better gastrointestinal profile, but more injection-site reactions, than twice-daily exenatide, and a less favourable gastrointestinal profile, but greater patient satisfaction, than sitagliptin.

Notes

Acknowledgements

The manuscript was reviewed by: S. Chinwong, Department of Pharmaceutical Care, Chiang Mai University, Chiang Mai, Thailand; A.D. Mooradian, Department of Medicine, University of Florida College of Medicine, Jacksonville, FL, USA; W.M. Valencia, Geriatric Research, Education and Clinical Center (GRECC), Miami VA Healthcare System, Miami, FL. USA. During the peer review process, AstraZeneca, the marketing-authorization holder of Bydureon® BCise®, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

E. D. Deeks is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

References

  1. 1.
    Faerch K, Torekov SS, Vistisen D, et al. GLP-1 response to oral glucose Is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study. Diabetes. 2015;64(7):2513–25.CrossRefGoogle Scholar
  2. 2.
    Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab. 2017;22(1):15–26.CrossRefGoogle Scholar
  3. 3.
    Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317–32.CrossRefGoogle Scholar
  4. 4.
    Samson SL, Garber AJ. A plethora of GLP-1 agonists: decisions about what to use and when. Curr Diabetes Rep. 2016;16(12):120.CrossRefGoogle Scholar
  5. 5.
    Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.CrossRefGoogle Scholar
  6. 6.
    American Diabetes Association. Pharmacological approaches glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S73–85.CrossRefGoogle Scholar
  7. 7.
    International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. Brussels: International Diabetes Federation; 2017.Google Scholar
  8. 8.
    Torekov SS. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL. Cardiovasc Res. 2018;114(10):e70–1.CrossRefGoogle Scholar
  9. 9.
    Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.CrossRefGoogle Scholar
  10. 10.
    Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.CrossRefGoogle Scholar
  11. 11.
    Byetta (exenatide) solution for injection in prefilled-pen: summary of product characteristics (EU).Södertälje (Sweden): AstraZeneca AB; 2018.Google Scholar
  12. 12.
    Byetta (exenatide) injection : US prescribing information. Wilmington (DE): AstraZeneca Phamaceuticals LP; 2015.Google Scholar
  13. 13.
    Bydureon 2 mg powder and solvent for prolonged-release suspension for injection. Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 2–20.Google Scholar
  14. 14.
    Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen. Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 21–39.Google Scholar
  15. 15.
    Bydureon® (exenatide extended-release) for injectable suspension, for subcutaneous use: US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP; 2018.Google Scholar
  16. 16.
    DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(d, l-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145–54.CrossRefGoogle Scholar
  17. 17.
    American Diabetes Association. Introduction: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S1–2.Google Scholar
  18. 18.
    American Diabetes Association. Improving care and promoting health in populations: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Suppl 1):S7–12.CrossRefGoogle Scholar
  19. 19.
    Garcia-Perez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.CrossRefGoogle Scholar
  20. 20.
    Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26(1):231–8.CrossRefGoogle Scholar
  21. 21.
    Spain CV, Wright JJ, Hahn RM, et al. Self-reported barriers to adherence and persistence to treatment with injectable medications for type 2 diabetes. Clin Ther. 2016;38(7):1653–64.e1.CrossRefGoogle Scholar
  22. 22.
    Frid A, Hirsch L, Gaspar R, et al. New injection recommendations for patients with diabetes. Diabetes Metab. 2010;36(Suppl 2):S3–18.CrossRefGoogle Scholar
  23. 23.
    Bydureon® BCise™ (exenatide extended-release) injectable suspension, for subcutaneous use : US prescribing information. Wilmington (DE): AstraZeneca Phamaceuticals LP; 2017.Google Scholar
  24. 24.
    Bydureon 2 mg prolonged-release suspension for injection in pre-filled pen (BCise). Bydureon summary of product characteristics (EU). Södertälje (Sweden): AstraZeneca AB; 2018. p. 40–59.Google Scholar
  25. 25.
    LaRue S, Springer J, Noderer M, et al. Evaluation of the use of exenatide once-weekly suspension autoinjector among patients with type 2 diabetes mellitus and health care professionals. J Diabetes Sci Technol. 2018.  https://doi.org/10.1177/1932296818798376.Google Scholar
  26. 26.
    Buss N, Ryan P, Baughman T, et al. Nonclinical safety and pharmacokinetics of Miglyol 812: a medium chain triglyceride in exenatide once weekly suspension. J Appl Toxicol. 2018;38(10):1293–301.CrossRefGoogle Scholar
  27. 27.
    Wysham CH, Rosenstock J, Vetter ML, et al. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(1):165–72.CrossRefGoogle Scholar
  28. 28.
    Gadde KM, Vetter ML, Iqbal N, et al. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19(7):979–88.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations